Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Offer Valuable Insights into Market Size, Market Share, Market Trends, and Projections Spanning from 2024 to 2031

Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Analysis and Latest Trends

Non-alcoholic Steatohepatitis (NASH) Biomarkers are substances that can be measured in the blood or other bodily fluids to indicate the presence of NASH, a progressive form of non-alcoholic fatty liver disease. These biomarkers help in the early diagnosis, prognosis, and monitoring of NASH, as well as in assessing response to treatment.

The Non-alcoholic Steatohepatitis (NASH) Biomarkers Market is expected to grow at a CAGR of 11.6% during the forecast period. This growth can be attributed to the increasing prevalence of NASH worldwide, rising awareness about the disease among healthcare professionals and patients, and the development of innovative biomarker-based diagnostic tests.

One of the key trends in the Non-alcoholic Steatohepatitis (NASH) Biomarkers Market is the focus on developing non-invasive and cost-effective biomarker tests that can accurately detect NASH in its early stages. This trend is driven by the need for simpler and less invasive diagnostic tools for NASH, which can help in better patient management and outcomes. Additionally, ongoing research and clinical trials are further contributing to the expansion of the NASH Biomarkers Market, with the introduction of new biomarkers that offer improved accuracy and specificity in detecting NASH.

Get a Sample PDF of the Report: https://www.reliablebusinessinsights.com/enquiry/request-sample/1686266

Non-alcoholic Steatohepatitis (NASH) Biomarkers Major Market Players

The non-alcoholic steatohepatitis (NASH) biomarkers market is highly competitive with key players such as Biopredictive, Gilead Sciences, GENFIT, Quest Diagnostics, Prometheus Laboratories, Exalenz Bioscience, ONE WAY LIVER, and Siemens Healthineers.

GENFIT is a prominent player in the NASH biomarkers market, with a focus on developing innovative diagnostics and therapeutics for liver diseases. The company has shown significant market growth due to its strategic collaborations and ongoing clinical trials for NASH treatment. GENFIT's future growth is promising as it continues to advance its pipeline of NASH biomarkers and potential therapies.

Quest Diagnostics, a leading provider of diagnostic information services, offers a range of NASH biomarker tests to aid in the diagnosis and monitoring of liver diseases. The company has seen steady market growth attributed to its extensive network of laboratories and strong brand reputation in the healthcare industry. Quest Diagnostics is expected to continue its expansion in the NASH biomarkers market by investing in research and development.

In terms of sales revenue, Gilead Sciences, a biopharmaceutical company, reported a total revenue of $21.7 billion in 2020, with a significant portion attributed to its NASH portfolio. Siemens Healthineers, a global leader in medical technology, reported a revenue of €14.5 billion in 2020, with continuous growth in its diagnostics segment including NASH biomarkers.

Overall, the NASH biomarkers market is expected to witness significant growth in the coming years due to the rising prevalence of NASH and increasing demand for advanced diagnostic solutions. Key players like GENFIT, Quest Diagnostics, Gilead Sciences, and Siemens Healthineers are well-positioned to capitalize on this growing market opportunity.

What Are The Key Opportunities For Non-alcoholic Steatohepatitis (NASH) Biomarkers Manufacturers?

The Non-alcoholic Steatohepatitis (NASH) Biomarkers market is witnessing significant growth due to the rising prevalence of NASH globally. Biomarkers such as fibroscan, MRI-PDFF, and blood-based tests are increasingly being utilized for the diagnosis and monitoring of NASH. The market is expected to expand further with advancements in diagnostic technologies and increasing awareness about NASH among healthcare professionals and patients. The future outlook for the NASH Biomarkers market is promising, with a growing focus on early detection and intervention to prevent the progression of NASH to more severe liver conditions.

Inquire or Share Your Questions If Any Before Purchasing This Report: https://www.reliablebusinessinsights.com/enquiry/pre-order-enquiry/1686266

Market Segmentation

The Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Analysis by types is segmented into:

Serum Biomarkers
Cytokeratin-18 (CK 18) Marker
Inflammatory Markers
Others

Non-alcoholic steatohepatitis (NASH) biomarkers market includes various types such as serum biomarkers, cytokeratin-18 (CK 18) marker, inflammatory markers, and others. Serum biomarkers are substances that can be measured in the blood to indicate the presence of NASH. CK 18 marker specifically targets liver cell death, while inflammatory markers show signs of inflammation in the liver. Other types of biomarkers may include genetic markers or imaging techniques to diagnose NASH and monitor disease progression.

Purchase this Report: https://www.reliablebusinessinsights.com/purchase/1686266

The Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Industry Research by Application is segmented into:

Hospitals
Diagnostic Centers
Others

The Non-alcoholic Steatohepatitis (NASH) Biomarkers Market finds application in hospitals, diagnostic centers, and other healthcare settings. Hospitals utilize these biomarkers for diagnosing and monitoring NASH in patients. Diagnostic centers offer specialized testing services for detecting NASH biomarkers. Other healthcare settings also benefit from the use of NASH biomarkers in research and clinical practice. Overall, the market for NASH biomarkers is essential for improving diagnosis, treatment, and management of NASH in various healthcare settings.

https://www.reliablebusinessinsights.com/non-alcoholic-steatohepatitis-nash-biomarkers-r1686266

In terms of Region, the Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Players available by Region are:

North America:

United States
Canada

Europe:

Germany
France
U.K.
Italy
Russia

Asia-Pacific:

China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia

Latin America:

Mexico
Brazil
Argentina Korea
Colombia

Middle East & Africa:

Turkey
Saudi
Arabia
UAE
Korea

The growth of Non-alcoholic Steatohepatitis (NASH) biomarkers market is expected to be significant in regions like North America, Europe, Asia-Pacific, USA, and China. North America and Europe are projected to dominate the market with a market share percentage valuation of 35% and 30% respectively, owing to the increasing prevalence of NASH in these regions. Asia-Pacific and USA are also anticipated to witness considerable growth, capturing market share percentages of 25% and 10% respectively.